Cancer Letters
Volume 223, Issue 2 , Pages 239-247 , 8 June 2005

Induction of apoptosis in human leukemia cells by MCS-C2 via caspase-dependent Bid cleavage and cytochrome c release

  • Min Kyoung Kim

      Affiliations

    • Department of Medical Genetics and Institute of Biomedical Science, Hanyang University College of Medicine, Seoul 133-791, South Korea
    • ,
  • Youl-Hee Cho

      Affiliations

    • Department of Medical Genetics and Institute of Biomedical Science, Hanyang University College of Medicine, Seoul 133-791, South Korea
    • ,
  • Jung Mogg Kim

      Affiliations

    • Department of Microbiology, Hanyang University College of Medicine, Seoul 133-791, South Korea
    • ,
  • Moon Woo Chun

      Affiliations

    • College of Pharmacy, Seoul National University, Seoul 151-742, South Korea
    • ,
  • Seung Ki Lee

      Affiliations

    • College of Pharmacy, Seoul National University, Seoul 151-742, South Korea
    • ,
  • Yoongho Lim

      Affiliations

    • Department of Applied Biology and Chemistry, Bio/Molecular Informatics Center, Konkuk University, Seoul 143-701, South Korea
    • ,
  • Chul-Hoon Lee

      Affiliations

    • Department of Medical Genetics and Institute of Biomedical Science, Hanyang University College of Medicine, Seoul 133-791, South Korea
    • Corresponding Author InformationCorresponding author. Tel.: +82 2 2290 0673; fax: +82 2 2298 5737.

Received 20 January 2004 ,Revised 13 September 2004 ,Accepted 20 October 2004.

References 

  1. Chu C-Y, Tsai Y-Y, Wang C-J, Lin W-L, Tseng T-H. Induction of apoptosis by esculetin in human leukemia cells. Eur. J. Pharmacol. 2001;416:25–32
  2. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 1997;275:1129–1132
  3. Nicholson DW, Ali A, Thornberry NA, Vaillancout JP, Ding CK, Gallant M, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995;376:37–43
  4. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose)polymerase by a protease with properties like ICE. Nature. 1994;371:346–347
  5. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, et al. Yama/CPP3β, a mammalian homolog of CED-3 is a crmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase. Cell. 1995;81:801–809
  6. Park SG, Cheon JY, Lee YH, Park J-S, Lee KY, Lee CH, et al. A specific inhibitor of cyclin-dependent protein kinase, CDC2 and CDK2. Mol. Cells. 1996;6:679–683
  7. Aszalos A, Lemanski P, Robison R, Davis S, Berk B. Identification of antibiotic 1037 as toyocamycin. J. Antibiot. (Tokyo). 1966;19:285
  8. Sverak L, Bonar RA, Langlois AJ, Beard JW. Inhibition by toyocamycin of RNA synthesis in mammalian cells and in normal and avian tumor virus-infected chick embryo cells. Biochim. Biophys. Acta. 1970;224:441–450
  9. Wilson WL. Phase I study with toyocamycin (NSC-63701). Cancer Chemother. Rep. 1968;52:301–303
  10. Clercq E, De J, Balzarini D, Madej F, Hansske , Robins MJ. Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin. J. Med. Chem. 1987;30:481–486
  11. Finch RA, Revankar GR, Chan PK. Structural and functional relationships of toyocamycin on NPM-translocation. Anti-Cancer Drug Des. 1997;12:205–215
  12. Gupta PK, Nassiri MR, Coleman LA, Wotring LL, Drach JC, Townsend LB. Synthesis, cytotoxicity, and antiviral activity of some acyclic analogues of the pyrrolo[2,3-d]pyrimidine nucleoside antibiotics tubercidin, toyocamycin, and sangivamycin. J. Med. Chem. 1989;32:402–408
  13. Krawczyk SH, Nassiri MR, Kucera LS, Kern ER, Ptak RG, Wotring LL, et al. Synthesis and antiproliferative and antiviral activity of 2′-deoxy-2′-fluoroarabinofuranosyl analogs of the nucleoside antibiotics toyocamycin and sangivamycin. J. Med. Chem. 1995;38:4106–4114
  14. Kim MK, Cho YH, Kim JM, Chun MW, Lee SK, Lim Y, et al. Inhibition of cell cycle progression in human promyelocytic leukemia HL-60 cells by MCS-C2, novel cyclin-dependent kinase inhibitor. J. Microbiol. Biotechnol. 2003;13:607–612
  15. Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drug: a cautionary note. Cancer Res. 1989;49:5870–5878
  16. Hickmann JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev. 1992;11:121–139
  17. Smets LA. Programmed cell death (apoptosis) and response to anti-cancer drugs. Anti-cancer Drugs. 1994;5:3–9
  18. Glazer RI, Peale AL. Comparison between the inhibitory activities of sangivamycin and thiosangivamycin on nuclear ribonucleic acid synthesis in L1210 cells in vitro. Biochem. Pharmacol. 1980;29:305–310
  19. Ritch PS, Helmsworth M. Pyrrolopyrimidine lethality in relation to ribonucleic acid synthesis in Sarcoma 180 cells in vitro. Biochem. Pharmacol. 1982;31:2686–2688
  20. Miller RL, Adamczyk DL, Miller WH, Koszalka GW, Rideout JL, Beacham LM, et al. Adenosine kinase from rabbit liver. II. Substrate and inhibitor specificity. J. Biol. Chem. 1979;254:2346–2352
  21. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 1996;86:147–157
  22. Reed J. Cytochrome c: Can't live with it—can't live without it. Cell. 1997;91:559–562
  23. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell death receptors. Cell. 1998;94:481–490
  24. Esposti MD. The roles of Bid. Apoptosis. 2002;7:433–440
  25. Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh J, Schlesinger PH. Pro-apoptotic cascade activates BID, which oligomerized BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 2000;7:1166–1173
  26. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 2000;102(1):43–53
  27. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995;14:5579–5588
  28. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, et al. FLICE, a novel Fadd-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell. 1996;85:817–827
  29. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Tomaselli KJ, Debatin KM, et al. Two CD95 (APO-1/Fas) signaling pathway. EMBO J. 1998;7:1675–1687
  30. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspase-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J. Cell Biol. 1999;144:281–292

PII: S0304-3835(04)00854-7

doi: 10.1016/j.canlet.2004.10.045

Cancer Letters
Volume 223, Issue 2 , Pages 239-247 , 8 June 2005

Article Tools

* Image Usage & Resolution